|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
IMMUNOBIOLOGY
From the First Department of Internal Medicine, Nagoya
University School of Medicine, Nagoya, Japan.
Histone deacetylase inhibitors (HDACIs) have been used to focus on
the effects of inducing gene expression through the acetylation of
histones which results in chromatin remodeling. The
study explored whether HDACIs could induce the expression of
costimulatory/adhesion molecules on acute myeloid leukemia (AML) cells,
thereby effectively inducing tumor immunity. The expression of CD80,
CD86, human leukocyte antigen (HLA)-DR, HLA-ABC, and intracellular
adhesion molecule-1 (ICAM-1) was tested in human AML cell lines after
the addition of HDACI, sodium butyrate (SB). Generally, increased
expression of CD86 was observed by SB treatment in a majority of cell
lines, and ICAM-1 was expressed in fewer cell lines. Essentially the same results were obtained using other HDACIs such as FR901228, trichostatin A, and trapoxin A. Quantitation of transcripts of CD86 accompanied with RNA synthesis inhibition assay and nuclear run-on
assay revealed that SB up-regulates the CD86 expression transcriptionally. Furthermore, chromatin immunoprecipitation experiments showed that HDACI treatment caused remarkable acetylation on histone H3 and H4 at CD86 promoter chromatin in vivo. In 30 clinical
AML samples, CD86 expression was significantly increased (P < .001) by SB treatment, and the expression of HLA-DR
and ICAM-1 was moderately increased (P < .05) by SB
treatment. Finally, the allogeneic mixed leukocyte reaction (allo-MLR)
against HL60 cells pretreated with SB was enhanced 4-fold compared with
allo-MLR obtained with non-treated HL60 cells. These results
suggest that the immunotherapeutic use of HDACIs may become a novel
tool for treatment of AML.
(Blood. 2000;96:3847-3856) Although a very high complete remission rate can be
obtained in acute myeloid leukemia (AML) by a combination therapy of
multiple drugs, chemotherapy leads to less than a 50% long-term
disease-free survival.1,2 Results of allogeneic bone
marrow transplantation (allo-BMT) suggest the existence of an
antileukemic immune response, the so-called graft-versus-leukemia (GVL)
effect. It has been indicated that donor-derived T cells play an
important role in eliminating the residual leukemic cells after
BMT.3,4 The current model of T-cell activation has been
presumed to require 2 signals. The first signal is specific, requiring
T-cell receptor recognition and binding to major histocompatability
complex (MHC) complex/antigen presented by an antigen-presenting cell
(APC). The second signal is nonspecific, resulting from the binding of ligands for the T-cell costimulatory receptors CD28 and CTLA-4, ie,
CD80/B7-1 and CD86/B7-2, respectively.
Results of an experimentally induced animal tumor model suggest that
rejection of immunogenic tumors is primarily mediated by T cells and
that the engagement of the TCR by MHC complex/peptide is generally not
sufficient to trigger a productive immunoresponse.5 Adequate expression of costimulatory/adhesion molecules is critical to
stimulate a potent T-cell response.6 Failure to receive these signals renders potential effector T cells anergic or tolerant, and such second signals provided by the APC through numerous surface molecules are required to promote complete T-cell activation. Of these
molecules, the B7 family members B7-1 (CD80) and B7-2 (CD86) have been
shown to be important.7-10 In addition, intracellular adhesion molecule-1 (ICAM-1), by binding to lymphocyte
function-associated antigen 1 (LFA-1) on the surface of lymphocytes,
can also be crucial for activating T lymphocytes.11,12
Among the major mechanisms of escape from immune surveillance, the
absence of a specific tumor antigen or down-regulation of MHC molecule
expression induces a lack of T-cell recognition of cancer cells.
Another major mechanism of escape from immune surveillance involves
defective expression of ligands for the T-cell costimulatory receptors
CD28 and CTLA-4, ie, CD80 and CD86, respectively, on the target cell
surface. AML cells generally express MHC class I and class II
molecules, but CD80, CD86, and ICAM-1 are not always expressed on AML
cells; thus these molecules can be the target of immunotherapy in
AML.13,14 Furthermore, it has been reported that the
T-cell stimulatory properties of leukemic cells can be up-regulated.
Through activation via CD40, B-cell lymphoma and leukemia cells express
high levels of human leukocyte antigen (HLA) and B7 molecules and
become efficient APCs for alloreactive T cells.15,16
Moreover, CD40-stimulated pre-B leukemia cells have been used to
generate leukemia-specific autologous cytolytic T
cells.17
Chromatin modification by histone acetyltransferase (HAT) or histone
deacetylase (HDAC) represents a fundamental mechanism of
transcriptional regulation.18,19 It has been proposed that histone acetylation promotes transcription, probably by relaxing specific segments of DNA and facilitating the binding of transcription factor.20 HDAC inhibitors (HDACIs) are thought to inhibit
the enzymatic activity of histone deacetylase and to enhance the
transcriptional activity of several genes. Currently known HDACIs,
including sodium butyrate (SB),21 trichostatin A
(TSA),22,23 trapoxin A (TPX),24 FR901228
(FR),25 and MS-27-275,26 have been known to
cause a variety of phenotypic changes, such as G1 and
G2/M arrest of cell cycle, morphological reversion of
transformed cells, differentiation,27,28 and cell growth
inhibition.29-31 It has been shown that butyrate stimulates production of fetal hemoglobin, and some beneficial effects
have been obtained in the treatment of thalassemia32 and
sickle cell disease.33 In cancer therapy, clinical trails of phenylbutyrate, which is used for the treatment of several cancers,
is now in phase I/II study and the drug may be a promising treatment
option for acute promyelocytic leukemia (APL) that is refractory to
all-trans-retinoic acid (ATRA) and arsenic
trioxide.34 Furthermore, we have recently reported that a
majority of AML cells other than APL cells could also be differentiated
by combination treatment with HDACIs and other
differentiation-inducible reagents such as ATRA and vitamin
D3.28 Modulation of immune responses through
acetylation and deacetylation is poorly understood. We hypothesized
that acetylation and deacetylation are among the major mechanisms in
the regulation of costimulatory/adhesion molecules.
In this study we examined the effects of HDACIs on the expression of
these molecules in AML cell lines and freshly isolated clinical samples
and showed immunomodulatory effects of HDACIs, which can be a new
therapeutic tool for immunotherapy in leukemia.
Cells and cell culture
HDACIs and other agents
Monoclonal antibodies and flow cytometric analysis The following fluorescein isothiocyanate (FITC)-conjugated antihuman monoclonal antibodies (mAbs) were used: CD80 (Immunotech International, Marseilles, France), CD86 (PharMingen, San Diego, CA), HLA-DR (Nichirei, Tokyo, Japan), HLA-ABC (Immunotech), and CD54 (Dako Japan, Kyoto, Japan). The cells were treated with HDACIs 48 hours before flow cytometric assay. For combination treatment, IFN- and SB
were added simultaneously 48 hours before assay. ATRA
(10 7 mol/L) was added to the cells to induce
differentiation in HL60, and the cells were incubated for 48 hours.
Flow cytometric analysis was performed as described. Briefly,
1 × 105 cells were incubated with isotype-matched
control antibody or anti-CD80, anti-CD86, anti-CD54, anti-HLA-DR, and
anti-HLA-ABC antibodies at 4°C for 30 minutes. After washing
twice with phosphate-buffered saline (PBS) supplemented with 2% FCS,
the cells were subjected to flow cytometric analysis (FACSCalibur;
Becton Dickinson, Mountain View, CA) with CELL Quest v3.1 software
(Becton Dickinson).
Propidium iodide staining for viability The cells were cultured in complete medium at 5 × 105 cells per mL in a 24-well plate. After treatment with HDACIs for 48 hours, the cells were collected and suspended in 0.5 mL PBS. We added propidium iodide (PI) (Sigma) at a final concentration of 1 µg/mL in PBS to each tube, and the mixture was incubated for 5 minutes at room temperature. Approximately 10 000 data events per sample were analyzed on FACSCalibur. Viable cells were defined with a forward scatter (FS)/PI gate.Detection of histone hyperacetylation by HDACI treatment Acid urea Triton X-100 (AUT) gel electrophoresis was performed as previously described.22 HL60 cells (2 × 106) were cultured for 6 hours with or without 1.0 mmol/L SB. Cellular histones were extracted and subjected to AUT gel electrophoresis. Histone hyperacetylation by HDACI treatment was detected in situ using antiacetylated histone H4 antibody (Upstate Biotechnology, Lake Placid, NY). HL60 cells were incubated for 3 hours with or without HDACIs and subjected to immunostaining. The antibody was used at 1:4000 dilution, and acetylated histones were detected by using labeling streptoavidine-biotin (LSAB) method.Chromatin immunoprecipitation HL60 cells were treated with 1.0 mmol/L SB for indicated periods. The cells (5 × 107) were fixed with formaldehyde (final concentration, 1%) at room temperature for 15 minutes. Soluble chromatin was made per manufacture's specifications (Upstate Biotechnology) with minor modification. Briefly, the cells were washed 2 times with cold PBS; suspended in 1.0 mL Pipes buffer with 5 mmol/L Pipes (pH 8.0), 85 mmol/L potassium chloride (KCl), and 0.5% NP40 containing protease inhibitors; and placed on ice for 10 minutes. After pelletizing the cells, they were resuspended in 250 µL sodium dodecyl sulfate (SDS) lysis buffer comprising 1% SDS, 10 mmol/L ethylenediamine tetraacetic acid (EDTA), and 50 mmol/L Tris-HCl (tris[hydroxymethyl] aminomethane [pH 8.1]); placed on ice for 10 minutes; and subjected to sonication of the lysate by using Bioruptor UCD-200TM (Cosmo Bio, Tokyo, Japan). After centrifugation, the supernatant fraction was diluted in 2.0 mL dilution buffer comprising 0.01% SDS, 1.1% Triton X-100, 1.2 mmol/L EDTA, 16.7 mmol/L Tris-HCl (pH 8.1), and 167 mmol/L sodium chloride (NaCl), and we used 20 µL diluted supernatant as input control. The chromatin solution was precleared by 80 µL Salmon Sperm DNA/Protein A Agarose Slurry (Upstate Biotechnology).The supernatant fraction was divided into 2 equal parts of 950 µL
each and subjected to immunoprecipitation with 5 µL antiacetylated histone H3 or H4 antibody (Upstate Biotechnology). The immunocomplex was recovered by adding 30 µL Salmon Sperm DNA/Protein A Agarose Slurry. The beads were washed 5 times per manufacturer's
specifications (Upstate Biotechnology). We added 250 µL elution
buffer with 1% SDS and 0.1 mmol/L NaHCO3, and the
beads were rotated at room temperature for 30 minutes. Then 5 mol/L
NaCl was added to reverse the formaldehyde cross-linking, and the
pellets were resuspended and treated with proteinase K, extracted with
phenol/chloroform, and precipitated with ethanol. The pellets
were precipitated with 20 µg glycogen as carrier and resuspended in
50 µL of 10 mmol/L Tris-HCl and EDTA. We used 10 µL of 50 µL DNA
solution for quantitative PCR. Quantitative PCR was performed using
SYBR Green PCR Master Mix (Perkin Elmer). For making the relative
standard curve, control DNA was prepared from HL60 cells, and 10-fold
dilution value of the DNA was used for standard curve. Primers used
were 5'-GCCCTCCTTGGTTATGCAGTC-3' and 5'-CATGACGTTAAGATGAGCCTGAA-3',
which can amplify the 301-base pair (bp) length fragment in the CD86
promoter ( The PCR mixture contained 200 nmol/L forward and reverse primers each, 25 µL SYBR Green PCR Master Mix, and 10 µL DNA solution. The total amount of reaction volume was 50 µL. Analysis was performed by the ABI-PRISM 7700 Sequence Detector System using Sequence Detector v1.6.3 software (both from Perkin Elmer). Using the same primer sets, conventional PCR was also performed with 10 µL DNA sample and 27 cycles. PCR products stained by ethidium bromide were visualized using a Gel Doc 1000 Video Gel Documentation System and quantitated by Molecular Analyst Software (Bio-Rad Laboratories, Hercules, CA). Relative quantitation of messenger RNA using real-time PCR method SB was added to each cell line to give a final concentration of 0.7 mmol/L in HL60 and 0.5 mmol/L in U937. CHX for protein inhibition experiments was applied 1 hour prior to SB treatment at a final concentration of 10 µg/mL. The cells were harvested at various times (0, 1, 3, 6, and 12 hours after SB treatment), and RNA was extracted from 107 cells using RNA STAT-60 (Tel-Test "B," Friendswood, TX) according to the manufacturer's specifications. The following reverse transcription for complementary DNA (cDNA) synthesis reaction was performed by the standard methodology. Using Primer Express v1.0 software (Perkin Elmer), we designed PCR primers for the amplification of cDNA derived from the messenger RNA (mRNA) of CD86, ICAM-1, and -actin. The primers used were as follows: CD86 forward
and reverse primers 5'-GGGCCGCACAAGTTTTGA-3' and
5'-GCCCTTGTCCTTGATCTGAA-3', respectively; ICAM-1 forward and reverse
primers 5'-TGCAGACAGTGACCATCTACAGC-3' and 5'-TCTGAGACCTCTGGCTTCGTC-3',
respectively; -actin forward and reverse primers
5'-ACAATGAGCTGCCTGTGGCT-3' and 5'-ATCACGATGCCAGTGGTACG-3', respectively. The TaqMan probe contains a reporter dye (FAM) at the
5'-end of the probe and a quencher dye (TAMRA) at the 3'-end of the
probe. The following sequences were used as probe: CD86 probe:
5'-(FAM)-TCGGACAGTTGGACCCTGAGACTTCAC-(TAMRA)-3'; ICAM-1: 5'-(FAM)-TTCCGGCGCCCAACGTGATT-(TAMRA)-3'; and -actin:
5'-(FAM)-CAGCCATGTACGTTGCTATCCAGGCTGT-(TAMRA)-3'. Real-time
PCR analysis was performed by the ABI-PRISM 7700 Sequence Detector
System according to the manufacturer's specifications. For relative
quantitation of each mRNA, we used the separate tube method and
calculated the relative quantity of each sample using relative standard
curves. The normalized amount of target mRNA was calculated by dividing
the amount of each target mRNA by the amount of -actin corresponding
to each sample.
mRNA synthesis inhibition ActD was dissolved in ethanol at 1 mg/mL and used at a final concentration of 3.5 ng/µL. HL60 cells were incubated with 0.7 mmol/L SB for 3 hours to raise the basal level of CD86 mRNA. After washing twice with PBS, the cells were preincubated with ActD for 30 minutes. Aliquots of cells pretreated with ActD were further incubated for the indicated time in the presence or absence of 0.7 mmol/L SB. RNA was extracted and subjected to real-time PCR using the same set of primers and probe described above.Nuclear run-on assay HL60 cells (5 × 107) were incubated for 3 hours with or without 1.0 mmol/L SB. The cells were washed twice with PBS and further incubated with 5 mL lysis buffer, which was made of 10 mmol/L Tris-HCl (pH 7.4), 10 mmol/L NaCl, 3 mmol/L magnesium dichloride (MgCl2), and 0.5% NP40, for 3 minutes on ice. Similar conditions were used for 3 washing steps, and the final nuclear pellet was suspended in 100 µL nuclear freezing buffer with 50 mmol/L Tris-HCl (pH 8.3), 40% glycerol, 5 mmol/L MgCl2, and 0.1 mmol/L EDTA. The nuclei were then mixed with 30 µL run-on buffer comprising 25 mmol/L Tris-HCl (pH 8.0); 12.5 mmol/L MgCl2; 750 mmol/L KCl; 1.25 mmol/L each of adenosine, guanosine, and cytidine 5'-triphosphate (ATP, GTP, and CTP, respectively) (Roche Diagnostics, Mannheim, Germany); and 3.7 MBq -32P-UTP
(phosphorous 32-uridine 5'-triphosphate) (Amersham Pharmacia Biotech,
Tokyo, Japan). After incubation at 30°C for 30 minutes, 15 µL
deoxyribonuclease I (DNase I) was added, and the assay was incubated
for another 15 minutes. Labeled transcripts were isolated using RNA
STAT-60 (Tel-Test "B") and purified according to the manufacturer's specifications. Full-length human CD86 DNA (gift from
Dr Lewis Lanier) and human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) DNA were applied to the membrane (Hybond-N, Amersham) using
Dott Blotter DB-200 (Sanplatec, Osaka, Japan) and fixed to the membrane
using ultraviolet (UV) cross-linker. An equal amount of radioactivity
(approximately 3 × 106 counts per minute of labeled RNA)
was used for the membrane hybridization assay. Data were normalized for
the content of GAPDH in each sample using the NIH Image version 1.6 software (National Institutes of Health, Bethesda, MD).
Allogeneic mixed leukocyte reaction To evaluate the immunomodulatory effects of SB against allogeneic leukocytes, HL60 and K562 cells treated with SB and peripheral blood mononuclear cells (PBMNCs) from healthy volunteers were prepared as the stimulator and responder, respectively. The cells were treated with 0.7 mmol/L SB for 48 hours, washed, and resuspended in RPMI 1640 supplemented with 10% human serum obtained from a volunteer donor. After irradiation with 75 Gy, 5 × 102 to 1 × 105 stimulator cells were added to 1 × 105 PBMNCs in each well of 96-well flat-bottomed culture plates (Microtest 96, Becton Dickinson). Lymphocyte proliferation after 5 days of culture was measured with the addition of hydrogen 3 (3H)-thymidine (ICN Biomedicals, Costa Mesa, CA) (37kBq [1 µCi] per well) for 18 hours prior to harvesting and determining incorporated radioactivity.Statistical methods Differences in the expression of each molecule (CD80, CD86, HLA-DR, HLA-ABC, and ICAM-1) between SB- and medium-treated clinical AML samples were analyzed using the Wilcoxon rank sum test.
SB enhances expression of costimulatory/adhesion molecules in AML cell lines in a cell-type-specific manner To determine the effect of HDACIs on the expression of CD80, CD86, HLA-DR, HLA-ABC, and ICAM-1 on the cell surface of AML, we tested 9 human AML cell lines for the action of SB by flow cytometric analysis (Figure 1). The cells were incubated for 48 hours in the presence or absence of SB at various concentrations. Cell viability was examined by both trypan blue dye exclusion and PI staining methods. The maximal concentration of SB for each cell line was decided by the fact that 70% of cells were kept viable during the analyses. The expression of CD80 was exclusively increased in NKM-1 cells and down-regulated in U937 cells by the addition of SB. In contrast, the expression of CD86 was up-regulated in 5 of 9 AML cell lines examined. CD86, but not CD80, was induced by SB in HL60, NB4, KG-1, ML-1, and U937 cells. In terms of ICAM-1, a significant increase in its expression was observed in HL60, NB4, and ML-1. The expression of HLA-DR, an MHC class II family member, was not increased by SB except in the case of KG-1 cells, which expressed HLA-DR at a high level before treatment. The expression of HLA-ABC, MHC class I antigen, was up-regulated in megakaryoblastic cell line MEG-O1. None of the molecules examined were affected in erythroleukemia cell line K562.
The potential of various HDACIs to induce expression of CD86 We then examined the difference in the ability to enhance the expression of CD86 among several HDACIs in HL60 cells. To define the ideal dose for the respective HDACI, various concentrations of each HDACI were added to the cells, and viability was examined by the PI exclusion method 48 hours after treatment (Figure 2A). We thereafter used each agent at the concentrations indicated as a closed circle ( ) to determine the
expression of CD86. As shown in Figure 2B, the induction of CD86
increased in a dose-dependent manner for all 4 HDACIs examined.
However, the ability to enhance the expression seemed to be different
among HDACIs compared with their cytotoxic effects. The treatment with
SB and FR seemed to enhance the expression more drastically than the
expression induced by TSA and TPX. Namely, treatment with 0.5 mmol/L SB
(the dose at which more than 80% of the cells were kept viable 48 hours after treatment) increased the mean fluorescence intensity (MFI) by 3-fold relative to the control level. However, 50 ng/mL TSA (the
concentration at which equivalent viability was obtained compared to
0.5 mmol/L SB) could only exhibit a 1.4-fold increase of MFI. These
results suggest that the potential to induce the expression of
CD86 may vary among HDACIs.
Acetylation of histones was observed by HDACI treatment To confirm whether HDACI treatment leads to histone acetylation, we performed AUT gel electrophoresis assay and immunostaining in situ using antiacetylated histone H4 antibody. AUT gel electrophoresis allows separation of each cellular histone (H1, H2A, H2B, H3, and H4), and acetylated histones can be separated as slower migrating proteins than unacetylated ones. The highly acetylated histone H4 was exclusively detected by the SB treatment for 6 hours (Figure 3A). We further analyzed histone acetylation by in situ immunostaining. The cells treated with TSA and SB were positively immunostained in situ by antiacetylated histone H4 antibody within 1 hour, and the number of positive cells increased gradually up to 3 hours after treatment (Figure 3B).
SB treatment causes hyperacetylation of histone H3 and H4 at CD86 promoter chromatin in vivo To directly assess whether HDACI-induced CD86 expression correlates with changes in the acetylation of histones, we took advantage of chromatin immunoprecipitation (ChIP) assay.35,36 Antibodies specific to acetylated histone H3 (lysines 9 and 14) and H4 (lysines 5, 8, 12, and 16) were used to immunoprecipitate soluble chromatin from cells treated with or without SB. The resulting genomic DNA was then analyzed by quantitative PCR using primers spanning approximately a 300-bp fragment of the CD86 promoter gene. We used SYBR Green PCR Master Mix for quantitative PCR. ChIP analysis with antibodies to acetylated H3 and H4 revealed that SB treatment actually caused a remarkable increase in acetylation of histone H3 and H4 at CD86 promoter chromatin in vivo within 3 hours. The acetylation level of histone H3 and H4 increased by 6.2- and 2.1-fold, respectively, after 3 hours of treatment with SB (Figure 3C). Another 2 experiments independently performed showed almost the same results (data not shown). For visualization, semiquantitative PCR was also performed for 27 to 30 cycles using the same primer sets and template DNA. The amplified products with 27 cycles are shown in Figure 3D. Similar to the data from real-time PCR, the increased acetylation level of histone H3 and H4 on the CD86 promoter was observed.Up-regulation of costimulatory molecules by HDACIs is not correlated with ATRA-induced differentiation in HL60 In the case of HL60, HDACIs alone used in the present study increased the expression of myeloid-lineage cell surface markers, but they were not sufficient to induce terminal differentiation revealed by morphological change and functional markers such as nitroblue tetrazolium (NBT) reduction activity.28 In contrast, treatment with ATRA significantly promotes cell differentiation of HL60, as indicated by morphology and functional assay.37 We thus examined the effect of ATRA on the induction of costimulatory/adhesion molecules. Treatment with ATRA alone for 48 hours could not enhance the CD86 expression (Figure 4), and this was consistently observed during the treatment with ATRA for 5 days (data not shown). This suggests that up-regulation of CD86 is not associated with cell differentiation in the case of HL60.
The potential to modulate the expression of costimulatory molecules
is different between SB and IFN- has been revealed to up-regulate several
costimulatory/adhesion molecules in monocytes and AML
blasts.13,38 We used 6 AML cell lines (HL60, NKM-1, KG-1,
Kasumi-1, U937, and ML-1) to compare the effects between SB and IFN-
and to evaluate whether SB enhances IFN--dependent action. Each
chemical was added either independently or simultaneously, incubated
for 48 hours, and then analyzed by FCM. The data from 3 representative
cell lines (HL60, NKM-1, and KG-1) are shown in Figure
5. In KG-1 cells, IFN- alone induced
CD80 expression but not CD86, whereas SB up-regulated CD86 but not
CD80. The minimal additive effect was observed by the combination
treatment on the expression of both CD80 and CD86. In NKM-1 cells,
single treatment with either IFN- or SB increased CD80 expression to
a similar degree, but no additive effect was observed. By a single
treatment with IFN-, CD80 expression was up-regulated in 3 of 6 cell
lines (KG-1, NKM-1, and U937), whereas the induction of CD86 expression
was observed in none of the 6 cell lines. HLA-DR expression was weakly
up-regulated in Kasumi-1 and NKM-1, whereas the expression of HLA-ABC
was highly up-regulated in all 6 cell lines. However, again there was
no observed additive effect of combination treatment on the expression
of HLA-DR and HLA-ABC in any of the 6 cell lines.
In terms of the expression of ICAM-1, a single treatment with IFN- Up-regulation of CD86 and ICAM-1 by SB is observed at the mRNA level and does not require new protein synthesis To confirm whether the induced expression of costimulatory/adhesion molecules by SB was regulated transcriptionally or posttranscriptionally, transcripts of these genes were assayed quantitatively by a real-time PCR method. Total RNA was prepared at various times (0-12 hours) after treatment. The cDNA synthesis reaction was performed using an equal amount (1 µg) of RNA. Analyses of real-time PCR and subsequent calculations were performed by the ABI-PRISM 7700 with Sequence Detector v1.6.3 software. The CD86 mRNA increased up to 7- to 10-fold at 12 hours after treatment in a time-dependent manner in both HL60 and U937. Similarly, the ICAM-1 mRNA increased approximately 6-fold relative to the control in HL60 cells. However, transcripts of ICAM-1 remained at the basal level in U937 cells. The alteration of mRNA in both CD86 and ICAM-1 is well correlated with the protein expression on the cell surface detected by flow cytometry (Figure 6A).
To further elucidate the mechanism of the up-regulation of transcripts, we examined whether active protein synthesis is necessary for the SB-induced expression of CD86 and ICAM-1. HL60 cells were preincubated in the presence of the protein-synthesis inhibitor CHX followed by further incubation for the indicated time in the presence or absence of 0.7 mmol/L SB. The representative data obtained 6 hours after SB treatment are shown in Figure 6B. The addition of CHX to SB-treated HL60 cells did not decrease the enhanced CD86 or ICAM-1 mRNA expression. In addition, the administration of CHX to untreated HL60 cells caused a superinduction of the basal CD86 and ICAM-1 mRNA, which is consistent with the previous report.39 This suggests that protein synthesis is not required for the SB-induced up-regulation of CD86 and ICAM-1 mRNA. The enhanced expression of CD86 by SB is regulated at the transcriptional level We next sought to unveil whether the up-regulation of CD86 mRNA by SB treatment was induced transcriptionally or via posttranscriptional modification. HL60 cells were pretreated with SB for 3 hours, subsequently incubated with ActD for 30 minutes, and then treated again with SB for the indicated time. Quantitative reverse transcriptase (RT)-PCR was performed to see how CD86 mRNA was down-regulated. As shown in Figure 7A, SB did not affect the disappearance of CD86 mRNA in cells treated with ActD. This suggests that the increase in expression of CD86 mRNA is not due to the altered stability of the RNA. We further performed a nuclear run-on assay to see whether de novo synthesis of CD86 mRNA is modified by SB. Nuclei from HL60 cells treated with or without SB for 3 hours were used for the assay of in vitro synthesis of mRNA. The production of CD86 mRNA was preferentially increased in nuclei from SB-treated cells compared with the untreated cells (1.68-fold increase), whereas no alteration of newly synthesized GAPDH mRNA was observed (1.07-fold) (Figure 7B). Namely, the newly synthesized CD86 mRNA normalized with GAPDH was increased by 1.5-fold by SB treatment. Overall, we conclude that SB-treated up-regulation of CD86 expression is regulated transcriptionally.
Induction of costimulatory/adhesion molecules by SB in AML samples To see how efficiently SB induces the costimulatory/adhesion molecules in clinical samples, we examined the effect of SB on 30 freshly isolated leukemic blasts. Viability was assessed by the trypan blue dye exclusion test. All samples contained more than 80% blast cells with viability greater than 80%. The fold induction of the intensity of expression derived from SB-treated AML cells relative to that from untreated cells is summarized in Table 1. The responsiveness of CD86 to SB treatment was not significantly different among FAB subtypes. When 30 samples were classified into 3 groups according to the karyotypes (normal karyotypes, karyotypes including t(8;21), and other abnormalities), only the marginal significance of the increase in CD86 expression was observed between normal karyotypes and t(8;21) (P = .04), as revealed by the Student t test. We further show the relative fluorescence intensity (RFI) of SB-pretreated and medium-treated cells according to the markers (Figure 8A). The expression of CD86 was significantly increased (P = .0007), as revealed by the Wilcoxon rank sum test. The alteration in the expression of HLA-DR and ICAM-1 showed borderline significance (P = .042 and P = .048, respectively). In contrast, the expression of CD80 and HLA-ABC was not significantly changed (P = .58 and P = .44, respectively). Four of 30 samples exhibited more than a 3-fold increase in expression of CD86, and the data from 3 of these 4 samples (UPN 8133, 8576, and 8646) are shown as the highest responders (Figure 8B). The fact that a significant increase in CD86 and a moderate increase in HLA-DR and ICAM-1 were observed in clinical AML samples by SB treatment is highly consistent with the results from AML cell lines.
SB induces allogeneic MLR in myelomonocytic leukemia cell line HL-60 To investigate the functional properties of SB-treated AML cells, the ability to stimulate an allo-MLR of HL60 cells treated with SB was compared with that of untreated cells. HL60 cells cultured with or without 0.5 mmol/L SB were used as the stimulator in allogeneic one-way MLR, with PBMNCs from healthy donors as responders. Proliferation was assessed by the uptake of 3H-thymidine during the last 18 hours. Results of a representative experiment are shown in Figure 9A. It can be seen that HL60 cells treated with SB had an enhanced capacity to stimulate lymphocyte proliferation compared with untreated HL60 cells. Essentially the same results were obtained in NB4 cells and KG-1 cells: SB-treated cells indicated higher potential to stimulate allo-MLR than medium-treated cells (data not shown). In contrast, SB treatment did not affect the allo-MLR in K562 cells, in which neither CD86 nor ICAM-1 was induced by SB (Figure 9B). These results support our notion that SB treatment stimulates allo-MLR partially through the up-regulation of CD86 and ICAM-1.
One of the novel therapeutic approaches currently being explored against hematologic malignancies is the manipulation of costimulatory molecules expressed on APCs or on tumor cells engineered to act as APCs. HDACIs are currently considered to be promising anticancer30,40 and differentiation-inducible agents in experimental models.28,41 Moreover, promising results are being found from clinical trials investigating the therapeutic efficacy of sodium phenylbutyrate in APL.34 However, the immunomodulatory effects of HDACIs are poorly understood.42,43 To our knowledge this is the first report that shows the possibility that HDACIs can be applied as immunomodulatory therapeutic modalities. In the present study we show that HDACIs up-regulate the expression of costimulatory/adhesion molecules on the AML cell lines and freshly isolated AML clinical samples. It is of interest that CD86 expression was up-regulated in 5 of 9 cell lines examined, and this enhancement was also seen in clinical samples with statistical significance. Additionally, ICAM-1 expression was also up-regulated in some cell lines and clinical samples. The role of CD86 expression in tumor immunity is not clear, but several tumor model systems do derive great benefit from CD86 expression.44-48 Knockout mice of CD80 display normal immune responses, whereas CD86 knockout mice are severely immunocompromised.49 More recently, it was reported that ICAM-1/LFA-1 T-cell costimulatory pathways are independent of CD86/CD28 pathways and that they may synergistically expand T-cell responses in vivo.11 Taken together with our present finding that allo-MLR is actually enhanced by HDACIs, it is possible that HDACIs can enhance the immunogeneity of leukemic cells through up-regulation of costimulatory/adhesion molecules. According to up-regulation of CD86 and ICAM-1 expression on the cell
surface, the enhancement of transcripts correlated well with that of
protein expression revealed by FCM. Our data indicate that CD86 mRNA
was up-regulated by HDACIs through transcriptional level, as evidenced
by mRNA synthesis inhibition, protein synthesis inhibition assays, and
nuclear run-on assay. In addition, we have shown that the CD86 promoter
was really targeted by HDACIs in vivo, as revealed by ChIP assay. Only
a few papers have reported on the regulation of CD80 and CD86
promoters. Recently characterization of CD86 promoter has been
reported.50 They show that CD86 transcription induced by
CD40 ligation in APC depends on the nuclear factor (NF)- It is interesting to find that the ability of TSA to enhance the CD86 expression was weaker than that of the other 3 HDACIs. To date, 8 isotypes of human HDAC genes have been identified.54-59 The selectivity and/or redundancy function of each HDAC, however, is not clear. Nonetheless, the selectivity of various HDACIs to release transcriptional repression caused by these different HDAC genes remains unveiled. Interestingly, the intensity to inhibit the enzymatic activity of HDACs by various HDACIs, including these 4 compounds used in the present study, varies widely (Dr M. Yoshida, Tokyo University, personal communication). The differences of the potential to induce CD86 gene expression may be a reflection of these differences. Future study to identify the expression profiles, such as using the DNA microarray technology, may clarify target genes of each HDACI including these costimulatory/adhesion molecules. The potential therapeutic implications of this work are substantial. HDACIs have been considered cell growth suppressors, apoptosis inducers, and differentiation inducers. We here offer another modality of HDACIs as antitumor drugs for use in immunotherapy. Ex vivo treatment of AML cells with HDACIs may generate functional APCs derived from AML cells and may be used in adoptive immunotherapies. Furthermore, the use of HDACIs in vivo may lead to the effective induction of antitumor CTL by the enhancement of costimulatory/adhesion molecules on AML blasts, which may eradicate leukemia blasts in association with the proapoptotic effect of HDACIs. In applying these HDACIs for clinical use, it may be necessary to recognize the heterogeneity of AML. Actually, the pattern of increase in the expression of costimulatory/adhesion molecules varies from patient to patient. Clarification of the mechanisms of the up-regulation may also explain the heterogeneity. In conclusion we have demonstrated that a single pharmacological agent interfering with the deacetylation of histone and nonhistone proteins establishes the induced expression of costimulatory/adhesion molecules in AML cells, which can then act as accessory molecules that are important for successful antigen presentation and recognition, T-cell activation, and leukemia-restricted cytotoxicity. The immunomodulatory effects of HDACIs on tumor cells in vivo, however, have not yet been reported. We are now starting to investigate whether HDACIs effectively stimulate the expression of these costimulatory/adhesion molecules in a mouse model. The functional consequences of HDACI treatment remain to be further elucidated.
The authors are grateful to Drs N. Emi, T. Naoe, and M. Yoshida for helpful suggestions. We thank M. Isomura, Y. Nakamura, C. Wakamatsu, and S. Suzuki for technical assistance. We also thank Drs Y. Morishita, Y. Kodera, I. Sugiura, T. Takeo, T. Kataoka, and K. Kitamura for the collaboration.
Submitted November 12, 1999; accepted August 3, 2000.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Masayuki Towatari, First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya 466-8550, Japan; e-mail: towatari{at}med.nagoya-u.ac.jp.
1. Minden M, Imrie K, Keating A. Acute leukemia in adults. Curr Opin Hematol. 1996;3:259-265[Medline] [Order article via Infotrieve].
2.
Lowenberg B, Downing JR, Burnett A.
Medical progress: acute myeloid leukemia.
N Engl J Med.
1999;341:1051-1062 3. Gale RP, Champlin RE. How does bone-marrow transplantation cure leukaemia? Lancet. 1984;2:28-30[Medline] [Order article via Infotrieve].
4.
Antin JH.
Graft-versus-leukemia: no longer an epiphenomenon [editorial].
Blood.
1993;82:2273-2277
5.
Schwartz RH.
A cell culture model for T lymphocyte clonal anergy.
Science.
1990;248:1349-1356 6. Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM. The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol Rev. 1996;153:5-26[Medline] [Order article via Infotrieve]. 7. Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, Nadler LM. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol. 1989;143:2714-2722[Abstract]. 8. Azuma M, Ito D, Yagita H, et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 1993;366:76-79[Medline] [Order article via Infotrieve]. 9. Lanier LL, O'Fallon S, Somoza C, et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol. 1995;154:97-105[Abstract].
10.
Linsley PS, Clark EA, Ledbetter JA.
T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1.
Proc Natl Acad Sciences U S A.
1990;87:5031-5035 11. Kim JJ, Tsai A, Nottingham LK, et al. Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo. J Clin Invest. 1999;103:869-877[Medline] [Order article via Infotrieve].
12.
Zuckerman LA, Pullen L, Miller J.
Functional consequences of costimulation by ICAM-1 on IL-2 gene expression and T cell activation.
J Immunol.
1998;160:3259-3268 13. Hirano N, Takahashi T, Takahashi T, et al. Expression of costimulatory molecules in human leukemias. Leukemia. 1996;10:1168-1176[Medline] [Order article via Infotrieve]. 14. Costello RT, Mallet F, Sainty D, Maraninchi D, Gastaut JA, Olive D. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition. Eur J Immunol. 1998;28:90-103[Medline] [Order article via Infotrieve].
15.
Ranheim EA, Kipps TJ.
Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal.
J Exp Med.
1993;177:925-935
16.
Schultze JL, Cardoso AA, Freeman GJ, et al.
Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.
Proc Natl Acad Sci U S A.
1995;92:8200-8204
17.
Cardoso AA, Seamon MJ, Afonso HM, et al.
Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells.
Blood.
1997;90:549-561 18. Ogryzko VV, Hirai TH, Russanova VR, Barbie DA, Howard BH. Human fibroblast commitment to a senescence-like state in response to histone deacetylase inhibitors is cell cycle dependent. Mol Cell Biol. 1996;16:5210-5218[Abstract]. 19. Bannister AJ, Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature. 1996;384:641-643[Medline] [Order article via Infotrieve]. 20. Lee DY, Hayes JJ, Pruss D, Wolffe AP. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell. 1993;72:73-84[Medline] [Order article via Infotrieve]. 21. Kruh J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem. 1982;42:65-82[Medline] [Order article via Infotrieve].
22.
Yoshida M, Kijima M, Akita M, Beppu T.
Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A.
J Biol Chem.
1990;265:17174-17179 23. Finnin MS, Donigian JR, Cohen A, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 1999;401:188-193[Medline] [Order article via Infotrieve].
24.
Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T.
Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase.
J Biol Chem.
1993;268:22429-22435 25. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res. 1998;241:126-133[Medline] [Order article via Infotrieve].
26.
Saito A, Yamashita T, Mariko Y, et al.
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Proc Natl Acad Sci U S A.
1999;96:4592-4597 27. Yoshida M, Horinouchi S, Beppu T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays. 1995;17:423-430[Medline] [Order article via Infotrieve]. 28. Kosugi H, Towatari M, Hatano S, et al. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia. 1999;13:1316-1324[Medline] [Order article via Infotrieve].
29.
Byrd JC, Shinn C, Ravi R, et al.
Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells.
Blood.
1999;94:1401-1408
30.
Saunders N, Dicker A, Popa C, Jones S, Dahler A.
Histone deacetylase inhibitors as potential anti-skin cancer agents.
Cancer Res.
1999;59:399-404 31. Rajgolikar G, Chan KK, Wang HC. Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. Breast Cancer Res Treat. 1998;51:29-38[Medline] [Order article via Infotrieve].
32.
Perrine SP, Ginder GD, Faller DV, et al.
A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.
N Engl J Med.
1993;328:81-86
33.
Atweh GF, Sutton M, Nassif I, et al.
Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease.
Blood.
1999;93:1790-1797
34.
Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP.
Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.
J Natl Cancer Inst.
1998;90:1621-1625
35.
Braunstein M, Rose AB, Holmes SG, Allis CD, Broach JR.
Transcriptional silencing in yeast is associated with reduced nucleosome acetylation.
Genes Dev.
1993;7:592-604 36. Chen H, Lin RJ, Xie W, Wilpitz D, Evans RM. Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell. 1999;98:675-686[Medline] [Order article via Infotrieve].
37.
Breitman TR, Selonick SE, Collins SJ.
Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid.
Proc Natl Acad Sci U S A.
1980;77:2936-2940 38. Fleischer J, Soeth E, Reiling N, Grage-Griebenow E, Flad HD, Ernst M. Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes. Immunology. 1996;89:592-598[Medline] [Order article via Infotrieve].
39.
Curiel RE, Garcia CS, Rottschafer S, Bosco MC, Espinoza-Delgado I.
Enhanced B7-2 gene expression by interferon-gamma in human monocytic cells is controlled through transcriptional and posttranscriptional mechanisms.
Blood.
1999;94:1782-1789
40.
Redner RL, Wang J, Liu JM.
Chromatin remodeling and leukemia: new therapeutic paradigms.
Blood.
1999;94:417-428
41.
Wang J, Saunthararajah Y, Redner RL, Liu JM.
Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.
Cancer Res.
1999;59:2766-2769 42. Kohge T, Gohda E, Okamura T, Yamamoto I. Promotion of antigen-specific antibody production in murine B cells by a moderate increase in histone acetylation. Biochem Pharmacol. 1998;56:1359-1364[Medline] [Order article via Infotrieve]. 43. Komatsu Y, Hayashi H. Histone deacetylase inhibitors up-regulate the expression of cell surface MHC class-I molecules in B16/BL6 cells. J Antibiot. 1998;51:89-91[Medline] [Order article via Infotrieve].
44.
Hodge JW, Abrams S, Schlom J, Kantor JA.
Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules.
Cancer Res.
1994;54:5552-5555 45. La Motte RN, Rubin MA, Barr E, Leiden JM, Bluestone JA, Mokyr MB. Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule. Cancer Immunol Immunother. 1996;42:161-169[Medline] [Order article via Infotrieve]. 46. Yang G, Hellstrom KE, Hellstrom I, Chen L. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol. 1995;154:2794-2800[Abstract].
47.
Agadjanyan MG, Kim JJ, Trivedi N, et al.
CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo.
J Immunol.
1999;162:3417-3427
48.
Mokyr MB, Kalinichenko TV, Gorelik L, Bluestone JA.
Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC- 315 tumor.
J Immunol.
1998;160:1866-1874 49. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233-258[Medline] [Order article via Infotrieve].
50.
Li J, Liu Z, Jiang S, Cortesini R, Lederman S, Suciu-Foca N.
T suppressor lymphocytes inhibit NF-kappa B-mediated transcription of CD86 gene in APC.
J Immunol.
1999;163:6386-6392
51.
Zhao J, Freeman GJ, Gray GS, Nadler LM, Glimcher LH.
A cell type-specific enhancer in the human B7.1 gene regulated by NF- kappaB.
J Exp Med.
1996;183:777-789
52.
Vanden Berghe W, De Bosscher K, Boone E, Plaisance S, Haegeman G.
The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter.
J Biol Chem.
1999;274:32091-32098
53.
Sheppard KA, Rose DW, Haque ZK, et al.
Transcriptional activation by NF-kappaB requires multiple coactivators.
Mol Cell Biol.
1999;19:6367-6378 54. Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p [see comments]. Science. 1996;272:408-411[Abstract].
55.
Yang WM, Inouye C, Zeng Y, Bearss D, Seto E.
Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3.
Proc Natl Acad Sci U S A.
1996;93:12845-12850
56.
Yang WM, Yao YL, Sun JM, Davie JR, Seto E.
Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family.
J Biol Chem.
1997;272:28001-28007
57.
Grozinger CM, Hassig CA, Schreiber SL.
Three proteins define a class of human histone deacetylases related to yeast Hda1p.
Proc Natl Acad Sci U S A.
1999;96:4868-4873
58.
Kao HY, Downes M, Ordentlich P, Evans RM.
Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression.
Genes Dev.
2000;14:55-66 59. Hu E, Chen Z, Fredrickson T, et al. Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J Biol Chem. 2000;15254-15264.
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  D. D. Vo, R. M. Prins, J. L. Begley, T. R. Donahue, L. F. Morris, K. W. Bruhn, P. de la Rocha, M.-Y. Yang, S. Mok, H. J. Garban, et al. Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824 Cancer Res., November 15, 2009; 69(22): 8693 - 8699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-N. Kim, N. H. Kim, W. Lee, D.-W. Seo, and Y. K. Kim Histone Deacetylase Inhibitor Induction of P-Glycoprotein Transcription Requires Both Histone Deacetylase 1 Dissociation and Recruitment of CAAT/Enhancer Binding Protein {beta} and pCAF to the Promoter Region Mol. Cancer Res., May 1, 2009; 7(5): 735 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Imai, K. Ochiai, and T. Okamoto Reactivation of Latent HIV-1 Infection by the Periodontopathic Bacterium Porphyromonas gingivalis Involves Histone Modification J. Immunol., March 15, 2009; 182(6): 3688 - 3695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Schmidt, K. Seeger, C. Scheibenbogen, R. Bender, M. Abdulla, S. Sussmilch, A. Salama, and A. Moldenhauer Histone deacetylase inhibition improves differentiation of dendritic cells from leukemic blasts of patients with TEL/AML1-positive acute lymphoblastic leukemia J. Leukoc. Biol., March 1, 2009; 85(3): 563 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Klimek, S. Fircanis, P. Maslak, I. Guernah, M. Baum, N. Wu, K. Panageas, J. J. Wright, P. P. Pandolfi, and S. D. Nimer Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes Clin. Cancer Res., February 1, 2008; 14(3): 826 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ishihama, M. Yamakawa, S. Semba, H. Takeda, S. Kawata, S. Kimura, and W. Kimura Expression of HDAC1 and CBP/p300 in human colorectal carcinomas J. Clin. Pathol., November 1, 2007; 60(11): 1205 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kato, K. Yoshimura, T. Shin, H. Verheul, H. Hammers, T. B. Sanni, B. C. Salumbides, K. Van Erp, R. Schulick, and R. Pili Synergistic In vivo Antitumor Effect of the Histone Deacetylase Inhibitor MS-275 in Combination with Interleukin 2 in a Murine Model of Renal Cell Carcinoma Clin. Cancer Res., August 1, 2007; 13(15): 4538 - 4546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M.E.I. Hellebrekers, K. Castermans, E. Vire, R. P.M. Dings, N. T.H. Hoebers, K. H. Mayo, M. G.A. oude Egbrink, G. Molema, F. Fuks, M. van Engeland, et al. Epigenetic Regulation of Tumor Endothelial Cell Anergy: Silencing of Intercellular Adhesion Molecule-1 by Histone Modifications. Cancer Res., November 15, 2006; 66(22): 10770 - 10777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Achachi, A. Florins, N. Gillet, C. Debacq, P. Urbain, G. M. Foutsop, F. Vandermeers, A. Jasik, M. Reichert, P. Kerkhofs, et al. Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo PNAS, July 19, 2005; 102(29): 10309 - 10314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Armeanu, M. Bitzer, U. M. Lauer, S. Venturelli, A. Pathil, M. Krusch, S. Kaiser, J. Jobst, I. Smirnow, A. Wagner, et al. Natural Killer Cell-Mediated Lysis of Hepatoma Cells via Specific Induction of NKG2D Ligands by the Histone Deacetylase Inhibitor Sodium Valproate Cancer Res., July 15, 2005; 65(14): 6321 - 6329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Byrd, G. Marcucci, M. R. Parthun, J. J. Xiao, R. B. Klisovic, M. Moran, T. S. Lin, S. Liu, A. R. Sklenar, M. E. Davis, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia Blood, February 1, 2005; 105(3): 959 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Moldenhauer, R. C. Frank, J. Pinilla-Ibarz, G. Holland, P. Boccuni, D. A. Scheinberg, A. Salama, K. Seeger, M. A. S. Moore, and S. D. Nimer Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins J. Leukoc. Biol., September 1, 2004; 76(3): 623 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Buda, D Qualtrough, M A Jepson, D Martines, C Paraskeva, and M Pignatelli Butyrate downregulates {alpha}2{beta}1 integrin: a possible role in the induction of apoptosis in colorectal cancer cell lines Gut, May 1, 2003; 52(5): 729 - 734. [Abstract] [Full Text]
|
|
|
|
|
|
A. P. Kohm, A. Mozaffarian, and V. M. Sanders B Cell Receptor- and {beta}2-Adrenergic Receptor-Induced Regulation of B7-2 (CD86) Expression in B Cells J. Immunol., June 15, 2002; 168(12): 6314 - 6322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Laribee and M. J. Klemsz Loss of PU.1 Expression Following Inhibition of Histone Deacetylases J. Immunol., November 1, 2001; 167(9): 5160 - 5166. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
16 to 
B consensus
site within the CD86 promoter. Similarly, NF-